Page last updated: 2024-11-01

ondansetron and Oligodendroglioma

ondansetron has been researched along with Oligodendroglioma in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Oligodendroglioma: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Siderov, J1
Zalcberg, J1
Chambers, B1
Fabinyi, G1

Other Studies

1 other study available for ondansetron and Oligodendroglioma

ArticleYear
Migraine following the use of a 5-hydroxytryptamine antagonist.
    Australian and New Zealand journal of medicine, 1993, Volume: 23, Issue:5

    Topics: Ergotamine; Female; Humans; Middle Aged; Migraine Disorders; Oligodendroglioma; Ondansetron; Sumatri

1993